Curanex Pharmaceuticals Inc (NASDAQ:CURX) Short Interest Update

Curanex Pharmaceuticals Inc (NASDAQ:CURX) saw a large decrease in short interest in July. As of July 15th, there was short interest totaling 11,829 shares, a decrease of 43.2% from the June 30th total of 20,835 shares. Based on an average daily volume of 81,338 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the company’s shares are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Curanex Pharmaceuticals stock. Citadel Advisors LLC purchased a new position in Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 64,067 shares of the company’s stock, valued at approximately $46,000.

Curanex Pharmaceuticals Trading Up 7.4%

NASDAQ CURX traded up $0.01 on Friday, hitting $0.21. 137,535 shares of the company were exchanged, compared to its average volume of 1,913,719. The company has a market cap of $5.82 million and a PE ratio of -0.76. The stock has a fifty day moving average of $0.27 and a 200-day moving average of $0.34. Curanex Pharmaceuticals has a 12 month low of $0.18 and a 12 month high of $9.18.

Curanex Pharmaceuticals (NASDAQ:CURX) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.11) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a report on Wednesday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.